Advertisement
U.S. markets open in 9 hours 8 minutes

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.5200-0.0800 (-3.08%)
At close: 04:00PM EDT
2.5011 -0.02 (-0.75%)
After hours: 07:19PM EDT

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
281 863 3000
https://www.lexpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Lonnel CoatsCEO & Director1.22MN/A1965
Mr. Jeffrey L. Wade J.D.President & CFO788.65kN/A1965
Mr. Brian T. CrumSenior VP, General Counsel & Secretary609.1kN/A1974
Dr. Kenneth B. Kassler-Taub M.D.Senior Vice President of Regulatory Affairs & Quality Assurance588.7kN/A1957
Dr. Craig B. Granowitz M.D., Ph.D.Senior VP & Chief Medical Officer671.14kN/A1966
Dr. Robert J. Lefkowitz M.D.Consultant & Independent Director50kN/A1944
Ms. Kristen L. AlexanderVice President of Finance & AccountingN/AN/A1968
Ms. Lisa M. DeFrancescoHead of Investor Relations & Corporate StrategyN/AN/A1980
Mr. Dixon TerryVice President of ComplianceN/AN/AN/A
Chas SchultzExecutive Director of Corporate Communications & Patient AdvocacyN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.